Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat

Journal of Steroid Biochemistry and Molecular Biology

Volumn 94, Issue 4, 2005, Pages 361-368

  Shirk, Rebecca A ^a   Zhang, Zhiming ^a   Winneker, Richard C ^a  

^a PFIZER INC   (United States)

Author keywords

Coagulation; Drospirenone; Estrogen; Hormone replacement therapy; Norethindrone acetate; Progestin; Thrombosis; Tissue factor pathway inhibitor; Trimegestone

Indexed keywords

ANTITHROMBIN; CHOLESTEROL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; FULVESTRANT; GESTAGEN; HORMONE RECEPTOR BLOCKING AGENT; MESSENGER RNA; NORETHISTERONE ACETATE; SEX HORMONE; TISSUE FACTOR PATHWAY INHIBITOR; TRIMEGESTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTROGEN ACTIVITY; FEMALE; NONHUMAN; OVARIECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALIA; NETA;

EID: 18044386375     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.12.026     Document Type: Article

References (57)

1. A. Psychoyos Hormonal control of ovo-implantation Vitam. Horm. 31 1973 201 256
2. J.P. Lydon, F.J. DeMayo, C.R. Funk, S.K. Mani, A.R. Hughes, C.A. Montgomery Jr., G. Shyamala, O.M. Conneely, and B.W. O'Malley Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities Genes Dev. 9 18 1995 2266 2278
3. Z. Zhang, C. Funk, S.R. Glasser, and J. Mulholland Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: effects of the antiprogestin, ZK 98.299 Endocrinology 135 3 1994 1256 1263
4. R. Sitruk-Ware Progestins and cardiovascular risk markers Steroids 65 10/11 2000 651 658
5. R.C. Winneker, D. Bitran, and Z.M. Zhang The preclinical biology of a new potent and selective progestin: trimegestone Steroids 68 10-13 2003 915 920
6. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group J. Am. Med. Assoc. 280 7 1998 605 613
7. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, and J. Ockene Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial J. Am. Med. Assoc. 288 3 2002 321 333
8. K.K. Koh, M.K. Horne III, and R.O. Cannon III Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women Thromb. Haemost. 82 2 1999 626 633
9. F.R. Rosendaal, F.M. Helmerhorst, and J.P. Vandenbroucke Oral contraceptives, hormone replacement therapy and thrombosis Thromb. Haemost. 86 1 2001 112 123
10. A. Cano, and W.M. Van Baal The mechanisms of thrombotic risk induced by hormone replacement therapy Maturitas 40 1 2001 17 38
11. R.W. Colman, J. Hirsh, V.J. Marder, and A.W. Clowes Overview of coagulation, fibrinolysis and their regulation R.W. Colman J. Hirsh V.J. Marder A.W. Clowes J.N. George Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2001 Lippincott Williams & Wilkins Philadelphia 17 20
12. K.G. Mann Biochemistry and physiology of blood coagulation Thromb. Haemost. 82 2 1999 165 174
13. W.M. van Baal, J.J. Emeis, M.J. van der Mooren, H. Kessel, P. Kenemans, and C.D. Stehouwer Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study Thromb. Haemost. 83 1 2000 29 34
14. J.J. Sidelmann, J. Jespersen, L.F. Andersen, and S.O. Skouby Hormone replacement therapy and hypercoagulability. Results from the prospective collaborative Danish climacteric study BJOG 110 6 2003 541 547
15. E. Hoibraaten, E. Qvigstad, T.O. Andersen, M.C. Mowinckel, and P.M. Sandset The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial Thromb. Haemost. 85 5 2001 775 781
16. M.S. Bajaj, J.J. Birktoft, S.A. Steer, and S.P. Bajaj Structure and biology of tissue factor pathway inhibitor Thromb. Haemost. 86 4 2001 959 972
17. R.J. Westrick, P.F. Bodary, Z. Xu, Y.C. Shen, G.J. Broze, and D.T. Eitzman Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice Circulation 103 25 2001 3044 3046
18. M. Ragni, P. Golino, P. Cirillo, A. Scognamiglio, O. Piro, N. Esposito, C. Battaglia, F. Botticella, P. Ponticelli, L. Ramunno, and M. Chiariello Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury Circulation 102 1 2000 113 117
19. D.T. Eitzman, R.J. Westrick, X. Bi, S.L. Manning, J.E. Wilkinson, G.J. Broze, and D. Ginsburg Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden Circulation 105 18 2002 2139 2142
20. Z.F. Huang, D. Higuchi, N. Lasky, and G.J. Broze Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice Blood 90 3 1997 944 951
21. A. Dahm, A. Van Hylckama Vlieg, B. Bendz, F. Rosendaal, R.M. Bertina, and P.M. Sandset Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis Blood 101 11 2003 4387 4392
22. P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, I. Juhan-Vague, and P.S. Group Endothelial cell markers and the risk of coronary heart disease: The prospective epidemiological study of myocardial infarction (PRIME) study Circulation 109 11 2004 1343 1348
23. G.M. Harris, C.L. Stendt, B.J. Vollenhoven, T.E. Gan, and P.G. Tipping Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives Am. J. Hematol. 60 3 1999 175 180
24. M.D. Luyer, S. Khosla, W.G. Owen, and V.M. Miller Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women J. Clin. Endocrinol. Metab. 86 8 2001 3629 3634
25. R.E. Peverill, H.J. Teede, J.J. Smolich, E. Malan, D. Kotsopoulos, P.G. Tipping, and B.P. McGrath Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII Clin. Sci. 101 1 2001 93 99
26. K.K. Koh, J.Y. Ahn, D.S. Kim, S.H. Han, M.S. Shin, W.S. Ryu, G.S. Park, T.H. Ahn, I.S. Choi, and E.K. Shin Effect of hormone replacement therapy on tissue factor activity, c-reactive protein, and the tissue factor pathway inhibitor Am. J. Cardiol. 91 3 2003 371 373
27. E.M. Bladbjerg, J.S. Madsen, S.R. Kristensen, B. Abrahamsen, K. Brixen, L. Mosekilde, and J. Jespersen Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study J. Thromb. Haemost. 1 6 2003 1208 1214
28. S.C. Bock Antithrombin III and heparin cofactor II R.W. Colman J. Hirsh V.J. Marder A.W. Clowes J.N. George Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2001 Lippincott Williams & Wilkins Philadelphia 321 329
29. J. Conard, B. Cazenave, M. Samama, M.H. Horellou, J.R. Zorn, and C. Neau AT III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women Thromb. Res. 18 5 1980 675 681
30. P.Y. Scarabin, G. Plu-Bureau, D. Zitoun, L. Bara, L. Guize, and M.M. Samama Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: Absence of dose-dependent effect on PAI-1 activity Thromb. Haemost. 74 3 1995 928 932
31. M. Cushman, B.M. Psaty, E.N. Meilahn, A.S. Dobs, and L.H. Kuller Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women Br. J. Haematol. 114 1 2001 162 168
32. M.R. Owens, C.D. Cimino, and J. Donnelly Measurements of rat plasma coagulation proteins during prolonged exposure to diethylstilbesterol Thromb. Res. 42 3 1986 343 354
33. D. Philibert, F. Bouchoux, M. Degryse, D. Lecaque, F. Petit, and M. Gaillard The pharmacological profile of a novel norpregnane progestin (trimegestone) Gynecol. Endocrinol. 13 5 1999 316 326
34. Z. Zhang, S.G. Lundeen, Y. Zhu, J.M. Carver, and R.C. Winneker In vitro characterization of trimegestone: a new potent and selective progestin Steroids 65 10/11 2000 637 643
35. P. Muhn, U. Fuhrmann, K.H. Fritzemeier, R. Krattenmacher, and E. Schillinger Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity Ann. N. Y. Acad. Sci. 761 1995 311 335
36. T. Luther, D.D. Dittert, M. Kotzsch, J. Erlich, S. Albrecht, N. Mackman, and M. Muller Functional implications of tissue factor localization to cell-cell contacts in myocardium J. Pathol. 192 1 2000 121 130
37. C. Lupu, F. Lupu, U. Dennehy, V.V. Kakkar, and M.F. Scully Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture Arterioscler. Thromb. Vasc. Biol. 15 11 1995 2055 2062
38. K. Enjyoji, M. Emi, T. Mukai, and H. Kato CDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI) J. Biochem. 111 5 1992 681 687
39. P. Ravinder, K.M. Nair, and B. Sivakumar Biological efficacy and plasma norethisterone levels of orally administered norethisterone enanthate in rat and hamster Ind. J. Physiol. Pharm. 42 4 1998 485 490
40. P.M. Spritzer, L.M. Barbosa-Coutinho, M. Poy, V. Orsi, N. Dahlem, and I.S. Silva Effects of norethisterone acetate and tamoxifen on serum prolactin levels, uterine growth and on the presence of uterine immunoreactive prolactin in estradiol-treated ovariectomized rats Braz. J. Med. Biol. Res. 28 1 1995 125 130
41. J. Garza-Flores, M. Menjivar, M. Cardenas, M. Reynoso, G.A. Garcia, and G. Perez Palacios Further studies on the antigonadotropic mechanism of action of norethisterone J. Steroid Biochem. Mol. Biol. 38 1 1991 89 93
42. H. Kuhl, W. Weber, W. Mehlis, J. Sandow, and H.D. Taubert Time- and dose-dependent alterations of basal and LH-RH-stimulated LH-release during treatment with various hormonal contraceptives Contraception 30 5 1984 467 482
43. O. Rugarn, A. Theodorsson, M. Hammar, and E. Theodorsson Effects of estradiol, progesterone, and norethisterone on regional concentrations of galanin in the rat brain Peptides 20 6 1999 743 748
44. S.G. Lundeen, Z. Zhang, Y. Zhu, J.M. Carver, and R.C. Winneker Rat uterine complement C3 expression as a model for progesterone receptor modulators: Characterization of the new progestin trimegestone J. Steroid Biochem. Mol. Biol. 78 2 2001 137 143
45. W. Kuhnz, A. Heuner, M. Humpel, W. Seifert, and K. Michaelis In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women Contraception 56 6 1997 379 385
46. M.S. Bajaj, M.N. Kuppuswamy, H. Saito, S.G. Spitzer, and S.P. Bajaj Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis Proc. Natl. Acad. Sci. U.S.A. 87 22 1990 8869 8873
47. M.S. Bajaj, M.N. Kuppuswamy, A.N. Manepalli, and S.P. Bajaj Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von willebrand factor in normal human tissues Thromb. Haemost. 82 3 1999 1047 1052
48. M. Narita, G. Bu, G.M. Olins, D.A. Higuchi, J. Herz, G.J. Broze Jr., and A.L. Schwartz Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo J. Biol. Chem. 270 42 1995 24800 24804
49. M.O. Palmier, L.J. Hall, C.M. Reisch, M.K. Baldwin, A.G. Wilson, and T.C. Wun Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits Thromb. Haemost. 68 1 1992 33 36
50. A.A. Creasey, A.C. Chang, L. Feigen, T.C. Wun, F.B. Taylor Jr., and L.B. Hinshaw Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock J. Clin. Invest. 91 6 1993 2850 2856
51. P.M. Sandset, M.L. Larsen, U. Abildgaard, A.K. Lindahl, and O.R. Odegaard Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): Levels in the normal population and relation to cholesterol Blood Coagul. Fibrinolysis 2 3 1991 425 433
52. E.M. Bladbjerg, S.O. Skouby, L.F. Andersen, and J. Jespersen Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor Hum. Reprod. 17 12 2002 3235 3241
53. M.E. Mendelsohn, and R.H. Karas The protective effects of estrogen on the cardiovascular system N. Engl. J. Med. 340 23 1999 1801 1811
54. D.M. Herrington, D.M. Reboussin, K.B. Brosnihan, P.C. Sharp, S.A. Shumaker, T.E. Snyder, C.D. Furberg, G.J. Kowalchuk, T.D. Stuckey, W.J. Rogers, D.H. Givens, and D. Waters Effects of estrogen replacement on the progression of coronary-artery atherosclerosis N. Engl. J. Med. 343 8 2000 522 529
55. W.F. Novotny, T.J. Girard, J.P. Miletich, and G.J. Broze Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma J. Biol. Chem. 264 31 1989 18832 18837
56. P.M. Sandset, H. Lund, J. Norseth, U. Abildgaard, and L. Ose Treatment with hydroxymethylglutaryl-coenzyme a reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system Arterioscler. Thromb. 11 1 1991 138 145
57. A.S. Bilsel, N. Onaran, H. Moini, and K. Emerk Long-term effect of 17beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC Thromb. Res. 99 2 2000 173 178